Drug intelligence / Profile preview

AFX-220

Development stage: Unknown
Lead developer: Afecta Pharmaceuticals
Modality: Small Molecules

Overview

AFX-220 is a small molecule therapeutic candidate developed by Afecta Pharmaceuticals for the treatment of neurodevelopmental disorders, including Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder (AD/HD). The drug's mechanism of action involves the dual modulation of monoamine neurotransmitter systems and cytokine-mediated inflammatory pathways. By targeting both neurochemical signaling and neuroinflammation, AFX-220 aims to address the complex pathophysiology of these conditions. It is currently in Phase 1 clinical development.

Beyond the preview

Go deeper on AFX-220.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFX-220.

Explore the full profile